

Published by  
Ministry of Health, Labour and Welfare



Translated by  
Pharmaceuticals and Medical Devices Agency



---

*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of PRECAUTIONS

## Axicabtagene ciloleucel, Idecabtagene vicleucel Ciltacabtagene autoleucel, Tisagenlecleucel Lisocabtagene maraleucel

August 29, 2023

### **Non-proprietary name**

Axicabtagene ciloleucel

Idecabtagene vicleucel

Ciltacabtagene autoleucel

Tisagenlecleucel

Lisocabtagene maraleucel

### **Safety measure**

PRECAUTIONS should be revised.

**Pharmaceuticals and Medical Devices Agency**

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan  
E-mail: [safety.info@pmda.go.jp](mailto:safety.info@pmda.go.jp)

Revised language is underlined.

Current	Revision
Important Precautions (N/A)	Important Precautions <u>An explanation on the possibility that this product cannot be provided due to reasons such as not conforming to specifications should be given to patients in advance.</u>

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.

**Pharmaceuticals and Medical Devices Agency**

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan  
E-mail: [safety.info@pmda.go.jp](mailto:safety.info@pmda.go.jp)